🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Nexviadyme 100 mg powder for concentrate for solution for infusion

    Disc Medicine

    Glycogen storage disease type II or acid maltase deficiency, Pompe disease

    approved small molecule active

    1 trial

  2. Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion

    Sanofi Winthrop Industrie

    Glycogen storage disease type II

    approved small molecule active

    1 trial

  3. Norfloxacino Sandoz 400 mg comprimidos EFG

    The George Institute

    Hospitalized patients with decompensated cirrhosis, diagnosed with bacterial infection evolution lasting for 48 hours or less.

    approved small molecule active

    1 trial

  4. Nucala 100 mg solution for injection in pre-filled pen, Nucala 100 mg solution for injection in pre-filled syringe, Nucala 100 mg solution for injection in pre-filled syringe, Nucala 100 mg solution for injection in pre-filled pen, Nucala 100 mg solution for injection in pre-filled pen, Nucala 100 mg solution for injection in pre-filled syringe

    GlaxoSmithKline

    severe asthma

    approved small molecule active

    1 trial

  5. OPDIVO 10 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets

    The George Institute

    Renal carcinoma

    approved small molecule active

    1 trial

  6. ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, RoActemra 162 mg solution for injection in pre-filled syringe., ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, RoActemra 162 mg solution for injection in pre-filled syringe., ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg sol

    The George Institute

    Adults patients suffering from rheumatoid arthritis and in adequate response to one or two targeted treatments.

    approved small molecule active

    1 trial

  7. Olanzapine

    United Therapeutics Europe Ltd

    Acute Agitation, Behavioural Emergency

    approved small molecule terminated

    1 trial

  8. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    AML (Acute Myeloid Leukemia)

    approved small molecule active

    1 trial

  9. Omvoh 100 mg solution for injection in pre-filled syringe, Omvoh 100 mg + 200 mg solution for injection in pre-filled syringe, Omvoh 100 mg solution for injection in pre-filled pen, Omvoh 100 mg solution for injection in pre-filled pen, Omvoh 100 mg + 200 mg solution for injection in pre-filled syringe, Omvoh 100 mg solution for injection in pre-filled syringe, Omvoh 100 mg solution for injection in pre-filled pen, Omvoh 100 mg + 200 mg solution for injection in pre-filled pen, Omvoh 100 mg + 200 mg solutio

    Eli Lilly Co.

    severely active ulcerative colitis (US) and CD (Crohn’s disease)

    approved small molecule active

    1 trial

  10. Oral prednisolone (30mg/day) for 28 days

    Hospital Authority, Hong Kong

    Esophageal Neoplasms

    approved small molecule active

    1 trial

  11. Osilodrostat (Isturisa)

    Ultragenyx UK Limited

    Mild Autonomous Cortisol Secretion (MACS)

    approved small molecule active

    1 trial

  12. Oxycodone Hydrochloride

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Analgesia, Patient-Controlled

    approved small molecule active

    1 trial

  13. Ozempic 1 mg solution for injection in pre-filled pen, Dapagliflozin 10 mg film-coated tablets

    The George Institute

    Type 2 diabetes

    approved small molecule active

    1 trial

  14. PEG-somatropin

    Changchun GeneScience Pharmaceutical Co.,

    Growth Hormone Deficiency

    approved mab active

    1 trial

  15. PLACEBO, ISMIGEN tabletki podjezykowe

    Lacuna Pharma Pty Ltd

    Respiratory Tract Infections

    approved small molecule active

    1 trial

  16. PROGRAF 1 mg capsule, Modigraf 0.2 mg granules for oral suspension, Envarsus 0.75 mg prolonged-release tablets, PROGRAF 0,5 mg capsule, Envarsus 4 mg prolonged-release tablets, Envarsus 1 mg prolonged-release tablets, PROGRAF 5 mg capsule, Modigraf 1 mg granules for oral suspension

    Disc Medicine

    pediatric kidney transplant recipients

    approved small molecule active

    1 trial

  17. PROPESS 10 mg, système de diffusion vaginal, PROSTINE E2 2 mg/3 g, gel vaginal, ANGUSTA 25 microgrammes, comprime, OXYTOCINE PANPHARMA 5 UI/1 ml, solution injectable

    Tour Hekla

    Labor Induction of women with an unfavorable Cervix after 24 hours of cervical ripening

    approved small molecule active

    1 trial

  18. Pantoprazole

    Takeda

    Gastroesophageal Reflux

    approved small molecule completed

    3 trials

  19. Pantoprazole

    Takeda

    Gastroesophageal Reflux Disease

    approved small molecule completed

    2 trials

  20. Paracetamol Biofarm, 500 mg, tabletki, Placebo - Nalgesin forte, Nalgesin Forte, 550 mg, tabletki powlekane

    Novo Nordisk A/S

    Knee osteoarthritis

    approved small molecule active

    1 trial

  21. Parecoxib

    The First People's Hospital of Lianyungang

    Postoperative Pain Management, Pain Threshold, Shoulder Pain, Laparoscopies

    approved small molecule completed

    1 trial

  22. Parecoxib

    The First People's Hospital of Lianyungang

    Emergence Delirium

    approved small molecule active

    1 trial

  23. Pariglasgene brecaparvovec

    Lacuna Pharma Pty Ltd

    Glycogen storage disease type Ia (GSDIa)

    approved small molecule active

    1 trial

  24. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Non-Small-Cell Lung

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources